Detalhe da pesquisa
1.
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.
N Engl J Med
; 390(6): 510-521, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324484
2.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
Nature
; 585(7823): 107-112, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32728218
3.
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.
Acta Derm Venereol
; 104: adv13467, 2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38348724
4.
Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT).
J Eur Acad Dermatol Venereol
; 38(4): 719-731, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084852
5.
Obesity is linked to disease severity in moderate to severe atopic dermatitis-Data from the prospective observational TREATgermany registry.
J Eur Acad Dermatol Venereol
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38661511
6.
[Immune-mediated inflammatory diseases in Germany : A cross-sectional analysis of comorbidities and pharmacotherapy]. / Chronische Entzündungserkrankungen in Deutschland : Eine Querschnittanalyse über Begleiterkrankungen und Arzneimitteleinsatz.
Z Rheumatol
; 83(3): 200-209, 2024 Apr.
Artigo
em Alemão
| MEDLINE | ID: mdl-36600054
7.
Guselkumab demonstrates long-term efficacy and maintenance of treatment response post-withdrawal in systemic-treatment naïve patients and non-responders to fumaric acid esters: Results from parts II and III of a randomised, active-comparator-controlled phase IIIb trial (POLARIS).
Br J Dermatol
; 2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38133615
8.
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Br J Dermatol
; 189(5): 540-552, 2023 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37488811
9.
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.
Br J Dermatol
; 189(6): 685-694, 2023 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37562034
10.
External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.
Dermatology
; 239(3): 362-367, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630943
11.
Measuring Quality of Life in Hidradenitis Suppurativa: Development and Validation of a Disease-specific Patient-reported Outcome Measure for Practice and Research.
Acta Derm Venereol
; 103: adv00859, 2023 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36129249
12.
The role of topical therapies along the psoriasis patient journey: An overview from the Symposium 'Tailoring topical psoriasis treatments to patients' needs and expectations' of the 30th EADV Congress 2021.
J Eur Acad Dermatol Venereol
; 37 Suppl 1: 3-8, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546464
13.
Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial.
J Eur Acad Dermatol Venereol
; 37 Suppl 5: 18-26, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37092275
14.
Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study.
J Eur Acad Dermatol Venereol
; 37(5): 1004-1016, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36606536
15.
A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30th EADV Congress 2021.
J Eur Acad Dermatol Venereol
; 37 Suppl 1: 14-19, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546465
16.
Management of psoriatic arthritis by dermatologists - a German nationwide survey.
J Dtsch Dermatol Ges
; 21(11): 1351-1357, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37814389
17.
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Lancet
; 397(10273): 475-486, 2021 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33549192
18.
Mechanism of anti-inflammatory effects of rifampicin in an ex vivo culture system of hidradenitis suppurativa.
Exp Dermatol
; 31(7): 1005-1013, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35048417
19.
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Br J Dermatol
; 186(6): 942-954, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981829
20.
Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care.
Dermatol Ther
; 35(1): e15193, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34741783